Jing Chen - 07 Dec 2022 Form 4 Insider Report for Biostage, Inc. (BSTG)

Role
Director
Signature
/s/ Chad Porter, Attorney-in-Fact
Issuer symbol
BSTG
Transactions as of
07 Dec 2022
Transactions value $
$26
Form type
4
Filing time
09 Dec 2022, 16:19:59 UTC
Previous filing
01 Jul 2022
Next filing
28 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSTG Common Stock Exercise of in-the-money or at-the-money derivative security $348,000 +174,000 +4.83% $2 210,000 07 Dec 2022 Direct
transaction BSTG Common Stock Sale -$347,974 -48,532 -23.11% $7.17 161,468 07 Dec 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSTG Warrants (right to buy) Exercise of in-the-money or at-the-money derivative security $0 -174,000 -100% $0* 0 07 Dec 2022 Common Stock 174,000 $2 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 7, 2022, the Reporting Person exercised a warrant to purchase 174,000 shares of common stock for $2 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in Biostage's withholding of 48,532 shares to pay the exercise price based on the daily VWAP of $7.1706, and issuing the remaining 125,468 shares of common stock.